Human data. Real confidence.

We are the gold-standard partner to drug developers. Combining our proprietary bioreactor technology and ex-vivo precision-cut tissue slices (PCTS), we bridge the translational gap and better predict clinical outcomes.

Does your data reflect human reality?

Defensible data designed for confident decisions when the cost of being wrong is greatest.

Learn more

Target identification and validation

Interrogate novel therapeutic targets in viable human tissue to build the real biological evidence needed to support confident early decisions.

Learn more

Lead screening and optimization

Test and rank novel interventions early to generate the decision-grade data needed to prioritize stronger candidates and enhance preclinical confidence.

Learn more

Pharmacology

Gain direct evidence of target engagement in human tissue to strengthen the translational case behind your program and support IND-enabling submissions.

Learn more

Drug safety

Assess tissue viability and emerging safety signals in human tissue to identify weak assets early and avoid unnecessary progression into formal GLP studies.

Learn more

The ultimate preclinical assurance 

Learn more

Combining the benefits of ex-vivo PCTS and our proprietary bioreactor technology, our platform delivers the definitive, human-relevant evidence needed to advance your drug discovery and development with confidence.

Tissue bioreactor technology

Proprietary bioreactor systems designed to preserve native tissue structure and function, enabling controlled, extended study in living human tissue.

Learn more

Tissue types and indications

Ethical procurement of viable human liver, lung and kidney tissue through established clinical partnerships for use in our PCTS platforms.

Learn more

Confidence built on real human biology

FibroFind is a preclinical CRO supporting biopharmaceutical organisations worldwide. Founded by world-leading experts, we uphold a defining ambition to de-risk drug discovery and development through the gold standard in human-relevant evidence, translating the irreplaceable complexity of human disease into evidence that moves programs forward with confidence.

Learn more about us Our mission

Led by recognized experts

Our executive leadership brings internationally recognized expertise in disease biology, translational science and human tissue research. FibroFind was founded by Professors Jelena Mann, Derek Mann, Fiona Oakley and Dr. Lee Borthwick, whose work helped establish the scientific foundations of the business.

Today, our wider leadership team builds on that legacy, combining deep academic, clinical and commercial expertise to guide global biopharma sponsors and translate complex scientific insight into decision-grade pipeline strategy.

Our leadership Quality and compliance

News and resources

News

FibroFind appoints leading transplant physician Professor Andrew Fisher as Chief Medical Officer

FibroFind appoints Professor Andrew Fisher as Chief Medical Officer as the company continues its global expansion.

Learn more

Poster

Combination of an Acetyl-Coenzyme A Carboxylase Inhibitor and Fibroblast Growth Factor-19 Reduced Tissue Triglyceride Content and Fibrosis in Human Precision-Cut Liver Slices

See how combining ACC inhibition with FGF19 reduced triglyceride accumulation and fibrosis in human precision-cut liver slices.

Learn more

News

FibroFind appoints new CEO to lead firm through next phase of growth

FibroFind appoints co-founder Lee Borthwick as CEO to lead its next phase of growth and scale its human-relevant preclinical testing platform.

Learn more

The evidence your program demands

Speak to our team about your program.

Get in touch